Harvard Bioscience (HBIO) & Neovasc Inc (US) (NVCN) Head-To-Head Comparison

Harvard Bioscience (NASDAQ: HBIO) and Neovasc Inc (US) (NASDAQ:NVCN) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Harvard Bioscience and Neovasc Inc (US), as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 2 0 3.00
Neovasc Inc (US) 0 0 4 0 3.00

Harvard Bioscience presently has a consensus target price of $9.00, suggesting a potential upside of 91.49%. Neovasc Inc (US) has a consensus target price of $3.35, suggesting a potential upside of 509.09%. Given Neovasc Inc (US)’s higher possible upside, analysts plainly believe Neovasc Inc (US) is more favorable than Harvard Bioscience.

Earnings and Valuation

This table compares Harvard Bioscience and Neovasc Inc (US)’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $104.52 million 1.57 -$4.30 million ($0.09) -52.22
Neovasc Inc (US) $9.51 million 4.56 -$86.49 million $0.27 2.04

Harvard Bioscience has higher revenue and earnings than Neovasc Inc (US). Harvard Bioscience is trading at a lower price-to-earnings ratio than Neovasc Inc (US), indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

61.7% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 19.0% of Neovasc Inc (US) shares are owned by institutional investors. 9.8% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Neovasc Inc (US)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -3.16% 1.11% 0.76%
Neovasc Inc (US) 268.35% -85.81% 23.39%

Volatility & Risk

Harvard Bioscience has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Neovasc Inc (US) has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.

Summary

Neovasc Inc (US) beats Harvard Bioscience on 7 of the 13 factors compared between the two stocks.

About Harvard Bioscience

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.

About Neovasc Inc (US)

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply